A blood based molecular test might direct recommendations for systemic therapies in early stage breast cancer patients receiving surgery with curative intent. A new study suggests that droplet digital polymerase chain reaction can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease
Minimal residual disease in breast cancer: in blood veritas.
SIRAVEGNA, GIULIA;BARDELLI, Alberto
2014-01-01
Abstract
A blood based molecular test might direct recommendations for systemic therapies in early stage breast cancer patients receiving surgery with curative intent. A new study suggests that droplet digital polymerase chain reaction can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
POST_2014-Siravegna et al_Minimal_4aperto.pdf
Open Access dal 02/06/2015
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
276.81 kB
Formato
Adobe PDF
|
276.81 kB | Adobe PDF | Visualizza/Apri |
|
2014-Minimal residual disease.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
410.03 kB
Formato
Adobe PDF
|
410.03 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
